Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2018/03/012853
CTRI/2018/03/012853
Not yet recruiting
Phase 1

Survival and functional outcome of geriatric patients operated for proximal femoral fractures; an anesthesiologists perspective.

PGIMER0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: null- proximal femoral fracture.

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Health Condition 1: null- proximal femoral fracture.
Sponsor
PGIMER
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
PGIMER

Eligibility Criteria

Inclusion Criteria

  • •Proximal femur fracture

Exclusion Criteria

  • •patients with polytrauma.
  • •patients with pathological fracture.
  • •refusal to give consent for inclusion in the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Assessment of functional outcome of elderly patients admitted neurosurgical department-comparison with the frailty before onset.All neurosurgical disease
JPRN-UMIN000034177Tokyo Women's Medical University Medical Center East500
Recruiting
Not Applicable
Functionality and Outcome in Older Patients with severe Aortic StenosisI35.0Aortic (valve) stenosis
DRKS00012494Klinikum NürnbergParaceslus Medizinische Privatuniversität150
Active, not recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.
EUCTR2016-002272-27-BESaarland University388
Active, not recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantationMedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-002272-27-ATSaarland University388
Active, not recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.
EUCTR2016-002272-27-PTSaarland University388